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Patient Blood Management
What Else?
Donat R. Spahn, MD, FRCA
P atient Blood Management is an evidence-based concept aiming at preemptively reducing theneed for red blood cell (RBC) transfusions to improve patient safety and outcome. Patient
Blood Management is based on 3 pillars: preoperative treatment of anemia and iron deficiency,
reduction of perioperative blood loss, and optimization of anemia tolerance including the
utilization of restrictive transfusion triggers. Safety and efficacy of patient blood management
has been shown in a variety of studies including 2 studies with more than 100,000 patients
each.1,2
Althoff et al3 in this issue of the journal present an impressive meta-analysis on studies that
assessed the impact of the implementation of at least 1 patient blood management measure in each of
the 3 pillars on outcome. The results are staggering (Table 1).
Given this impressive safety and efficacy, the question arises why patient blood management
has not yet been introduced in all hospitals worldwide as a standard. A number of physicians may be
overwhelmed by the large number (>100) of patient blood management measures that have been
described.4 In an initial phase of the introduction of patient blood management, I advise focusing on
the following 7 measures:
1. Preoperative anemia treatment
2. Blood sparing surgical techniques with meticulous hemostasis
3. Use of cell salvage
4. Use of tranexamic acid
5. Advanced individualized and goal-directed coagulation management including monitoring and
use of coagulation factor concentrates
6. Postoperative anemia treatment with i.v. iron
7. Restrictive transfusion triggers.
Even the introduction of these 7 key measures may seem difficult to a number of
physicians. Therefore, the European Union and the National Blood Authority of Australia have
issued implementation guides.5,6 These guides provide some help. They, however, need to be
adapted to the local situation in each hospital. In some hospitals a patient blood management
program may be initiated by the board of directors with specific resources allocated. In most
hospitals, patient blood management programs, however, started small and developed consecu-
tively over years. In the latter context, the leader of the patient blood management program needs
to be defined first; in many hospitals, this is a particularly enthusiastic anesthesiologist. The
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second step is to choose the best-suited surgical discipline, which
at many places is orthopedic surgery due long scheduling times
allowing easy preoperative anemia treatment.7,8 Then it is crucial
to act data based. This means that data need to be collected
systematically regarding preoperative anemia, perioperative blood
loss, and transfusions and postoperative complications, length of
hospital stay, and costs. This data collection needs to start long
before the start of a patient blood management program to have a
reliable baseline and continue thereafter. These data from within
an individual hospital will convince implicated physicians and
result in better program adherence. These data will convince other
surgical disciplines and result in expansion of the program to these
other surgical disciplines. Finally, these data will convince the
Board of Directors and result in resource allocation for the patient
blood management program.
Despite many aspects being clarified today, there are issues that
need future research or particular attention. One is the question of
whether preoperative iron deficiency without concomitant anemia
requires treatment. Preoperative iron deficiency in cardiac surgery
resulted in increased RBC transfusions and fatigue9 and a trend toward
a longer hospital length of stay.10There is, however, hardly any data in
noncardiac surgery and this certainly requires future research.
The use of tranexamic acid has been shown to be safe and to
reduce RBC transfusions in most all surgical disciplines.11 The
prophylactic use of tranexamic acid thus can be recommended in
most patients undergoing major surgery.
Advanced individualized and goal-directed coagulation man-
agement including monitoring and use of coagulation factor con-
centrates has been shown to reduce significantly transfusions and
mortality in a variety of surgical settings from trauma treatment12 to
cardiac surgery.13
The preoperative administration of i.v. iron to treat iron defi-
ciency anemia is well known and increasingly used. The postoperative
use of i.v. iron, however, is much less common despite the fact that
there are several prospective randomized studies documenting safety
and efficacy.14,15 Clearly, this area deserves greater clinical attention.
The future potential of patient blood management is extremely
high. Patients, treated at centers that have not yet implemented
patient blood management will benefit in all domains listed in
Table 1. In centers that have only implemented some measures,
patients will benefit more with the introduction of additional mea-
sures. Patients, treated at centers that have introduced multiple
measures already may benefit from a more consistent application
of these measures. Finally yet importantly, patient blood manage-
ment has traditionally been implemented in surgery. Patient blood
management principles can, however, also be used in most of the
internal medicine specialties including oncology.16
As with each program, costs are an issue. Many are concerned
about additional costs of a patient blood management program. All
big programs, however, consistently report major cost savings, in
Germany,1 in Australia,2 in the United States,17 and in Switzerland.18
These reported cost savings are blood product acquisition cost. They,
however, represent just about a third of the true, that is, activity-based
costs, which are relevant for hospitals.19 The focus on blood product
acquisition cost thus significantly underestimates the cost savings. In
addition, the savings due to avoided complications and mortality
need to be considered as well. It may be difficult to calculate the
exact treatment cost of each complication. Nevertheless, from a
patient and economics point of view it is certainly worthwhile
avoiding any complication and mortality.20
Now that safety and efficacy of patient blood management has
systematically been confirmed by this meta-analysis, the stage is set
for worldwide implementation. Conversely, not implementing
patient blood management represents substandard care.
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Transfusion rate 39% <0.00001 207,006
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Hospital LOS 0.45 day <0.00001 219,850
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Acute renal failure 26% <0.00001 166,955
Infection rate 9% <0.03 192,987
Thromboembolic events 25% <0.00001 170,189
Mortality 11% <0.02 221,528
LOS indicates length of stay.
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